grant
Laboratory And Pre-clinical Studies Of Parainfluenza Viruses
Organization NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESLocation UNITED STATES
NIHUS FederalResearch GrantFY20250-11 years oldA549Active ImmunizationActive vaccinationAcute Laryngotracheo-Bronchitis VirusAcute Laryngotracheobronchitis VirusAcylneuraminyl hydrolaseAffectAgeAnimal ExperimentsAnti-viral AgentsAntibodiesAntigensAttenuatedAttenuated VaccinesB23Blood SerumBovine SpeciesCA virusCRADACattleCell BodyCell Culture TechniquesCellsChildChild YouthChildhoodChildren (0-21)Chimera ProteinChimeric ProteinsClinical EvaluationClinical ResearchClinical StudyClinical TestingClinical TrialsCodeCoding SystemCodonCodon NucleotidesCollaborationsComplementComplement ProteinsConchae NasalesCooperative Research and Development AgreementCricetinaeCroup-Associated VirusCytoplasmic DomainCytoplasmic TailDNA Molecular BiologyDNA mutationDevelopmentDiseaseDisorderEarly-Stage Clinical TrialsEngineeringEpitheliumFusion ProteinGeneralized GrowthGenesGenetic ChangeGenetic defectGenetic mutationGlycoproteinsGrowthHPIV1HPIV2HPIV3HamstersHamsters MammalsHemadsorption Type 2 VirusHemadsorption Virus 1Hemadsorption Virus 2HemagglutininHumanHuman Parainfluenza Virus 1Human Parainfluenza Virus 2Human Parainfluenza Virus 3IFNImmunizationIn VitroInfantInfectionInterferonsIntranasal AdministrationIntranasal Drug AdministrationLaboratory StudyLeadLifeLive-attenuated VaccineLungLung Respiratory SystemMembraneMissense MutationModern ManModificationMolecular BiologyMolecular ConfigurationMolecular ConformationMolecular StereochemistryMolecular VirologyMutationN-Acylneuraminate GlycohydrolasesNIH Vaccine Research CenterNPMNPM1NPM1 geneNasalNasal Passages NoseNasal turbinate bone structureNeuraminidaseNoseNucleoproteinsORFsOligosaccharide SialidaseOpen Reading FramesOrthopneumovirusPara-Influenza Virus Type 1Para-Influenza Virus Type 2Para-Influenza Virus Type 3Parainfluenza Virus Type 2Pb elementPhasePhase 1 Clinical TrialsPhase I Clinical TrialsPhase I StudyPhenotypePhosphoproteinsPneumoviridaePneumovirinaePneumovirusPolymeraseProtein Coding RegionProtein ConformationProteinsPublicationsRSV VaccinesReportingRespiratory Syncytial Virus VaccinesRespiratory System, Nose, Nasal PassagesRespiratory infectious agentRespiratory syncytial virusRespiratory tract pathogenScientific PublicationSerotypingSerumSialidaseSiteSpinal ColumnSpineSystemTimeTissue GrowthTurbinatesVaccine Clinical TrialVaccinesVero CellsVertebral columnViralViral AntigensViral Gene ProductsViral Gene ProteinsViral ProteinsVirionVirusVirus ParticleVirus ReplicationWorkagesanimal experimentanti-viral compoundanti-viral drugsanti-viral medicationanti-viral therapeuticanti-viralsattachment protein Gattenuateattenuatesattenuationbackbonebovidbovinecell culturecell culturesclinical testcomplementationconformationconformationalconformational stateconformationallyconformationscowdevelopmentaldisulfide bondexo alpha sialidaseexperimental animalexperimental animalsgenome mutationheavy metal Pbheavy metal leadimmunogenimmunogenicimmunogenicityimmunoprophylaxisin vivokidslead candidatelive vaccinelive vaccinesmanufacturemembrane structuremissense single nucleotide polymorphismmissense single nucleotide variantmissense variantneutralizing antibodynon-human primatenonhuman primateontogenyparainfluenza virusparainfluenza virus type 1parainfluenza virus type 3particlepediatricphase 1 studyphase I protocolpre-clinical studypreclinical studyprogramsresearch clinical testingrespiratoryrespiratory pathogenresponsereverse geneticsvaccine candidatevectorviral multiplicationviral replicationvirus antigenvirus multiplicationvirus proteinyoungster
Description preview
In recent years, we have focused on using a PIV3-based vector to express RSV antigen, providing a bivalent vaccine against the two most important pediatric viral respiratory pathogens. The vector is one that we previously developed, called rB/HPIV3, which consists of bovine PIV3 in which the F and HN genes have been replaced by those of HPIV3.…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click